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ABSTRACT
In parallel to the increased use of computed tomography, iodinated contrast agents are increasingly becom-
ing a source of excess iodide. Iodinated contrast agents may induce thyroid dysfunction in exposed patients, 
especially in the presence of an underlying thyroid disease. Thus, an ordinary dose of the contrast used for 
the imaging, can induce hyper or hypothyroidism in a patient with subtle thyroid disease. This review will 
briefly discuss the physiology of iodine and the clinical evaluation of iodine induced thyroid dysfunction.
Keywords: hyperthyroidism; hypothyroidism; iodinated contrast media
INTRODUCTION
In parallel to the increased use of computed tomog-
raphy (CT), iodinated contrast agents are increas-
ingly becoming a source of excess iodide. Iodine 
content of intravenous contrast used routinely for 
a CT scan, highly exceeds the recommended daily 
dose of iodine intake. Iodinated contrast agents may 
induce thyroid dysfunction in exposed patients, 
especially in the presence of an underlying thyroid 
disease. This short review focuses on iodine induced 
hyper and hypothyroidism and alterations caused by 
contrast agents on thyroid scintigraphy.
Role of iodine in normal physiology of thyroid
Thyrocytes express the sodium iodide symporter 
(NIS) at their basolateral membrane, and transport 
iodide inside the cell through this gate and against 
an electrical gradient. Iodide is then organified 
into tyrosyl residues of thyroglobulin (TG), in a 
reaction catalyzed by thyroid peroxidase (TPO). 
Thyroglobulin (TG) contains monoiodothyronine, 
diiodothyronine, triiodothyrosine (T3), and thyrox-
ine (T4) which are stored in colloid until T3 and T4 
are released into the blood (1).
Effect of iodinated contrast media on thyroid
Radiographic iodinated contrast media (RICM) 
is increasingly becoming a source of excess iodide 
due to common use of CT scans (2). Low osmo-
lar contrast media have fewer side effects and are 
preferable, especially in patients with renal dysfunc-
tion. However, they contain a higher ratio of iodide 
atoms (3).
Both ionic and nonionic contrast media con-
tain iodine at amounts ranging between 
300-370 mcg/mL (2). Usually, 50-100 ml of con-
trast media is given per CT scan. This means that 
a patient undergoing a contrast CT scan receives 
about 15-37 g total iodine and 2500-5000 µg free 
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iodine. Conversion of non-bioavailable iodine to 
free iodide in the body further contributes to the 
iodide load, especially in the presence of renal insuf-
ficiency (4). In patients with normal thyroid func-
tion, excess iodine persists in the body for 4-8 weeks 
after the exposure to contrast media (5).
Subtle changes (a small decrease followed by an 
increase in free T3 and free T4, and a decrease in 
TSH followed by a rapid increase – all within nor-
mal limits) in thyroid function, after the exposure to 
iodinated contrast media, can be detected in normal 
subjects (6).
Iodine induced hypothyroidism
A retrospective analysis of patients exposed to con-
trast media showed an association between the con-
trast exposure and hypothyroidism. The duration 
between the exposure and incident hypothyroidism 
varied between 50-294 days (7).
In patients with a history of thyroid lobec-
tomy, Graves’ disease, postpartum thyroiditis, or 
Hashimoto’s thyroiditis the follicular cells may fail 
to escape from the Wolff Chaikoff effect, after the 
exposure to excess iodine. As a result, iodine can 
induce hypothyroidism in these patients (8).
Other factors implied in iodine induced hypothy-
roidism are: down regulation of TPO (9), decreased 
organification of iodide (9), failure to decrease NIS 
expression (10), and autoimmunity (11).
Patients with underlying thyroid disease or patients 
who present with signs and symptoms of hypothy-
roidism, should be monitored for contrast induced 
hypothyroidism. If the TSH level is higher than 
10  mIU/L, the replacement with L thyroxine 
should be performed. Repeated TSH measurements 
in 6-12  weeks are necessary to titrate the dose. 
Contrast induced hypothyroidism is a self-limited 
dysfunction. The treatment may be stopped within 
a few months. However, continuous monitoring of 
these patients is suggested since they are under risk 
of permanent hypothyroidism, especially if they 
have an underlying thyroid autoimmunity (12).
Iodine induced thyrotoxicosis
Iodine induced thyrotoxicosis was first described in 
1821, and is known as Jod-Basedow phenomenon. 
For iodine induced thyroid hyperfunction to occur, 
the Wolff Chaikoff effect need to be impaired. The 
risk factors for iodine induced hyperthyroidism 
include diffuse goiter, nodular goiter, latent Graves’ 
disease, and iodine deficiency (13).
A study including 101 euthyroid patients who 
underwent coronary angiography, reported a 6% 
incidence of subclinical hyperthyroidism, 8  weeks 
after the exposure (14). A retrospective case-control 
study found a 2-3 times increased risk of hyperthy-
roidism after contrast exposure in patients with a 
prior history of thyroid dysfunction. The median 
follow-up period in this study was 9 months (7).
Other studies yielded contradicting results. No case 
of thyrotoxicosis was observed after iodine contain-
ing contrast exposure in 56 patients, in a study from 
the United States (15).
Another study from Italy on more than 
1700  patients, reported an incidence of 1.9% 
hyperthyroidism after iodine exposure. However, in 
this study, anti-thyroid medications and radioactive 
iodine ablation were used in some of the patients, 
prior to the contrast exposure (16).
Elderly patients with probably undiagnosed thyroid 
nodules may develop subclinical hyperthyroidism 
(suppressed TSH and normal free T4 levels), as long 
as 8 weeks after the injection (17). These patients 
may present with atypical symptoms like weight loss 
and atrial fibrillation (18,19). Thyroid dysfunction 
is associated with increased morbidity in elderly. 
Thus, it is important to consider thyrotoxicosis in 
elderly patients with non-specific symptoms and 
signs in the setting of recent contrast exposure.
Considering that iodinated contrast is a risk fac-
tor for thyrotoxicosis, the question is if all patients 
should be screened before performing a radiological 
procedure. Practically, the answer is “no”.
The Contrast Media Safety Committee of the 
European Society of Urogenital Radiology (ESUR) 
published a guideline about iodine induced thyroid 
dysfunction, in 2015 (4). According to this guideline, 
routine monitoring of thyroid function before a CT 
scan is not indicated, however, patients under the risk 
should be carefully monitored after the exposure to 
iodine containing contrast media. Of note, the guide-
line states that manifest hyperthyroidism is an abso-
lute contraindication for contrast enhanced imaging.
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Patients with thyrotoxicosis present with symptoms 
such as tremor, palpitations, excessive sweating, 
and weight loss. Laboratory tests show a suppressed 
TSH with elevated free T3 and free T4 levels. Since 
radioactive iodine uptake is inversely related to 
plasma iodine levels, low iodine uptake is observed 
in patients with contrast induced thyrotoxicosis. 
A spot urinary iodine level may be helpful for the 
diagnosis and in the follow-up (20). Repeated expo-
sure to iodine should be avoided in these patients. 
Contrast induced thyrotoxicosis is a self-limited 
condition. Beta blocker or methimazole can be 
given to symptomatic patients.
Prophylactic treatment for iodine induced hyper-
thyroidism is a matter of debate. Data is insufficient 
to support the use of thionamides or perchlorate 
for the prevention (21). The Endocrine Society 
Guideline suggests prophylactic antithyroid ther-
apy with methimazole or potassium perchlorate 
(200 mcg 2-3 times a day), in patients who have a 
high risk of contrast induced thyrotoxicosis or who 
have underlying cardiac arrhythmias (13).
In addition to thyroid dysfunction, contrast media 
exposure also precludes treatment with 131I for thyro-
toxicosis or for differentiated thyroid cancer (DTC). 
Contrast exposure also affects the diagnostic accu-
racy of thyroid scintigraphy. The proper timing of 
131I scintigraphy, after the exposure to intravenous 
contrast, is not known. So some authors suggest 
postponing a diagnostic scintigraphic study or radio-
active iodine treatment for at least 2 months, after 
the exposure to intravenous contrast media (22,23). 
However, a retrospective review of 1023  patients 
with DTC, who underwent a preoperative contrast 
enhanced CT scan, revealed similar urinary iodine 
excretion rates, measured at 1 month and 6 months 
after the contrast exposure (24).
Practical points:
•	 Patients	 with	 an	 underlying	 thyroid	 dis-
ease-  e.g.,  Hashimoto thyroiditis or subtotal 
thyroidectomy - may develop hypothyroidism 
after exposure to iodinated contrast. Although 
the exact time for testing is not known, it 
seems feasible to monitor these patients within 
6-8 weeks after the contrast exposure.
•	 Patients	 with	 an	 underlying	 thyroid	 dis-
ease- e.g., Graves disease or nodular goiter- may 
develop hyperthyroidism after exposure to 
iodinated contrast. Although the exact time for 
testing is not known it seems feasible to mon-
itor these patients within 6-8  weeks after the 
contrast exposure.
•	 It	 is	 important	 to	 consider	 contrast	 induced	
thyrotoxicosis in elderly patients with atypical 
symptoms like weight loss and atrial fibril-
lation. Even subclinical hyperthyroidism is 
associated with increased morbidity in elderly 
patients.
•	 Repeated	exposure	to	iodinated	contrast	should	
be avoided in a patient with a prior history of 
contrast induced thyrotoxicosis.
•	 Documented	thyrotoxicosis	is	an	absolute	con-
traindication for procedures with iodinated 
contrast.
•	 Prophylactic	 treatment	 for	 iodine	 induced	
hyperthyroidism is a matter of debate. 
Thionamides or potassium perchlorate may be 
considered in patients with the high risk.
•	 Iodinated	 contrast	 exposure	 delays	 the	 treat-
ment or diagnostic scanning of patients with 
differentiated thyroid cancer. So the radiologist 
and endocrinologist should coordinate for an 
appropriate timing of such a procedure or con-
sider other diagnostic imaging methods, like 
magnetic resonance imaging.
CONCLUSION
Exposure to iodinated contrast media may induce 
hyper and hypothyroidism in patients, especially 
in those with an underlying thyroid disease, such 
as nodular goiter, Graves’ disease, or Hashimoto’s 
thyroiditis. Although routine screening with thy-
roid function tests is not feasible, careful evaluation 
of selected patients with risk factors is important. 
Special attention should be paid to elderly patients 
who may present with nonspecific symptoms and 
signs. Contrast exposure may also lead to unwanted 
delays in the management of differentiated thyroid 
cancer with radioactive iodine (RAI), so physicians 
should be careful about the proper indication and 
timing of contrast CT scans. Although contrast 
induced thyroid dysfunction is a self-limited state, 
follow-up of the patients for the development of a 
permanent thyroid disease is advised.
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